Trials with RLY-2608
Every colorectal cancer trial that includes this drug. Those looking for patients come first.
Showing 1–1 of 1
NCT05216432
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients w…